These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 7093108)

  • 1. Bioavailability of dihydroergotamine in man.
    Little PJ; Jennings GL; Skews H; Bobik A
    Br J Clin Pharmacol; 1982 Jun; 13(6):785-90. PubMed ID: 7093108
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low oral bioavailability of dihydroergotamine and first-pass extraction in patients with orthostatic hypotension.
    Bobik A; Jennings G; Skews H; Esler M; McLean A
    Clin Pharmacol Ther; 1981 Nov; 30(5):673-9. PubMed ID: 6794970
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of dihydroergotamine in healthy volunteers and in neurological patients after a single intravenous injection.
    Kanto J; Allonen H; Koski K; Koulu M; Lammintausta R; Mäntylä R; Kleimola T; Siirtola T
    Int J Clin Pharmacol Ther Toxicol; 1981 Mar; 19(3):127-30. PubMed ID: 7228454
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The pharmacokinetics of dihydroergotamine in the beagle dog after a single intravenous injection and after a continuous intravenous infusion.
    Kanto J; Allonen H; Kleimola T; Mäntylä R
    Acta Pharmacol Toxicol (Copenh); 1980 Apr; 46(4):241-4. PubMed ID: 7368942
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The pharmacokinetics and bioavailability of subcutaneously administered dihydroergotamine, heparin and the dihydroergotamine-heparin combination.
    Schran HF; Bitz DW; DiSerio FJ; Hirsh J
    Thromb Res; 1983 Jul; 31(1):51-67. PubMed ID: 6612697
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dihydroergotamine increases the bioavailability of orally administered etilefrine.
    Hengstmann JH; Hengstmann R; Schwonzen S; Dengler HJ
    Eur J Clin Pharmacol; 1982; 22(5):463-7. PubMed ID: 6126364
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Venous tonus-modifying effect, pharmacokinetics and undesired effects of dihydroergotamine].
    Barthel W
    Z Gesamte Inn Med; 1984 Sep; 39(17):417-28. PubMed ID: 6390997
    [TBL] [Abstract][Full Text] [Related]  

  • 8. On the treatment of migraine. Pharmacokinetic-pharmacodynamic relationships for a programmed release formulation of dihydroergotamine administered orally in the human.
    Aylward M; Davies DE; Maddock J; Robinson PR; Jones M
    Cephalalgia; 1983 Aug; 3 Suppl 1():146-50. PubMed ID: 6616596
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic investigation of oral and i.v. dihydroergotamine in healthy subjects.
    Wyss PA; Rosenthaler J; Nüesch E; Aellig WH
    Eur J Clin Pharmacol; 1991; 41(6):597-602. PubMed ID: 1815973
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The pharmacokinetics of dihydroergotamine in the beagle.
    Mäntylä R; Kleimola T; Kanto J
    Int J Clin Pharmacol Biopharm; 1978 Mar; 16(3):124-8. PubMed ID: 649230
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship between the venoconstrictor activity of dihydroergotamine and its pharmacokinetics during acute and chronic oral dosing.
    de Marées H; Welzel D; de Marées A; Klotz U; Tiedjen KU; Knaup G
    Eur J Clin Pharmacol; 1986; 30(6):685-9. PubMed ID: 3533566
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dihydroergotamine in idiopathic orthostatic hypotension: short-term intramuscular and long-term oral therapy.
    Fouad FM; Tarazi RC; Bravo EL
    Clin Pharmacol Ther; 1981 Dec; 30(6):782-9. PubMed ID: 7030580
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dihydroergotamine: pharmacokinetics, pharmacodynamics, and mechanism of venoconstrictor action in beagle dogs.
    Müller-Schweinitzer E; Rosenthaler J
    J Cardiovasc Pharmacol; 1987 Jun; 9(6):686-93. PubMed ID: 2442535
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intrapulmonary and intravenous administrations of dihydroergotamine mesylate have similar cardiovascular effects in the conscious dog.
    Shrewsbury SB; Stonerook M; Okikawa JK
    Br J Pharmacol; 2008 Jul; 154(6):1254-65. PubMed ID: 18500365
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interaction of dihydroergotamine and triacetyloleandomycin in the minipig.
    Martinet M; Kiechel JR
    Eur J Drug Metab Pharmacokinet; 1983; 8(3):261-7. PubMed ID: 6606577
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Venoconstrictor effects of dihydroergotamine after intranasal and intramuscular administration.
    Aellig WH; Rosenthaler J
    Eur J Clin Pharmacol; 1986; 30(5):581-4. PubMed ID: 3758146
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety, tolerability, and pharmacokinetics of a single orally inhaled dose of PUR3100, a dry powder formulation of dihydroergotamine versus intravenous dihydroergotamine: A Phase 1 randomized, double-blind study in healthy adults.
    Bodie S; Curran AK; Gonzalez-Nelson AC; Perry JM; Manning DC; Wasilewski MM
    Headache; 2024 Jun; 64(6):643-651. PubMed ID: 38717120
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low bioavailability as a cause of apparent failure of dihydroergotamine in orthostatic hypotension.
    Olver IN; Jennings GL; Bobik A; Esler M
    Br Med J; 1980 Jul; 281(6235):275-6. PubMed ID: 7427244
    [No Abstract]   [Full Text] [Related]  

  • 19. Pharmacodynamics and pharmacokinetics of dihydroergotamine (DHE) in conscious beagle dogs.
    Müller-Schweinitzer E
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1988; 115(1-2):162-5. PubMed ID: 2459013
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of ponsinomycin on the pharmacokinetics of dihydroergotamine administered orally.
    Couet W; Mathieu HP; Fourtillan JB
    Fundam Clin Pharmacol; 1991; 5(1):47-52. PubMed ID: 2066050
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.